Influence of Baseline Smoking Status on Intensive Blood Pressure Control: Results From the STEP Randomized Trial.

Can J CardiolApr 21, 2026 (epub)
Clinical ResearchCardiologyGeriatricsInternal Medicine (General)

Sifei Chen, Yufei Ji, Ruixue Yang et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of the STEP randomized trial evaluated the impact of baseline smoking status on cardiovascular outcomes in 8489 elderly hypertensive patients. Current smokers exhibited a higher adjusted risk of primary cardiovascular outcomes (hazard ratio, 1.39) and stroke (hazard ratio, 1.66) compared to nonsmokers, despite no significant interaction with intensive systolic blood pressure control.

Key findings

  • Current smokers had a higher adjusted risk of primary cardiovascular outcomes (hazard ratio, 1.39).
  • Current smokers had a higher adjusted risk of stroke (hazard ratio, 1.66).
  • Fewer current smokers reached the intensive SBP target during the first 9 months.

Why it matters

Understanding the differential impact of smoking on cardiovascular risks in hypertensive patients is crucial for tailoring treatment strategies. This study highlights the need for careful monitoring and management of blood pressure in smokers.

Source

PubMed · PMID 42025692

Published in Can J Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.